485.30
-1.58%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Thyrocare Technologies
Its shares trade on NSE under the ticker THYROCARE.NS. It has been listed since 9 May 2016. In the fiscal year to 31 December 2025, it reported revenue of ₹8.22bn and net income of ₹1.63bn. At that date it held total assets of ₹7.47bn and shareholders' equity of ₹5.86bn.
Thyrocare Technologies Ltd. engages in provison of indepedent diagnostic and pathological laboratory services. The company is headquartered in Navi Mumbai, Maharashtra. The company went IPO on 2016-05-09. The firm has diagnostic chains that conduct a range of medical diagnostic tests and profiles of tests that is focused on early detection and management of health disorders and diseases. The firm's segments include Diagnostic Testing Services, Imaging Services and Others. The Diagnostic Testing Services segment includes diagnostic and testing services, selling of consumables used for collection and promotion of pathology. The Imaging Services includes diagnostic and imaging services, selling of radio-pharmaceutical, selling of consumables for reporting. The Others segment include the sale of testing equipment and consumables, and selling of glucometer and glucostrips under the brand, Sugarscan. The firm has a centralized fully automated diagnostic testing laboratory, regional processing laboratories, a medical cyclotron facility and PET-CT facilities across India.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 9 May 2016
- Employees
- 1,645
- Website
- thyrocare.com ↗
Leadership
Pay as last reported
- Mr. Rahul GuhaExecutive Chairman of the Board, Chief Executive Officer, Managing Director, since 2022₹56.4m
- Mr. Vikram GuptaChief Financial Officer
- Mr. Brijesh KumarCompliance Officer, Company Secretary₹686,250
- Mr. Hardik DedhiaNon-Executive Non-Independent Director
- Mr. Alok JagnaniNon-Executive Non-Independent Director, since 2023₹11.9m
- Dr. Dhaval ShahNon-Executive Non-Independent Director
- Mr. Dharmil ShethNon-Executive Non-Independent Director, since 2021
- Dr. Prapti GiladaNon-Executive Independent Director₹800,000
- Dr. Indumati GopinathanNon-Executive Independent Director₹600,000
- Mr. Nishant ShahNon-Executive Independent Director₹350,000
- Mr. Anandh SundarNon-Executive Independent Director₹350,000
- Dr. Harshil VoraNon-Executive Independent Director₹300,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 57
- Environment
- 51
- Social
- 64
- Governance
- 56
- Direct emissions (scope 1)
- 95.04 t
- Energy emissions (scope 2)
- 4,754.6 t
- Women in the workforce
- 22.56%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Headquartered in Navi Mumbai with 1,645 employees
- Offers diagnostic and pathological laboratory services
- Operates centralized and regional laboratories across India
Weaknesses
- No specific weaknesses mentioned in the provided information
- No details on financial performance or market share provided
- No information on competitive disadvantages
Opportunities
- Expansion of diagnostic chains for early detection of health disorders
- Growth in Diagnostic Testing Services segment including consumables sales
- Potential for imaging services growth with PET-CT facilities
Threats
- No specific threats mentioned in the provided information
- No market competition details provided
- No regulatory or industry challenges described
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.